|
| |
Sloning and the Kornberg group at Stanford
University starting evaluation project regarding the synthesis of a
Statistically Randomized Gene Library
Munich, Germany, April 24, 2008 / b3c newswire / -
Sloning BioTechnology and Roger Kornberg’s group at Stanford University are
working on a project to synthesize a gene mutant library where selected codons
are introduced in a statistically expected and controlled ratio at preselected
positions within a given DNA sequence.
Sloning will utilize its core technology, Slonomics™, a unique DNA engineering
platform using defined sets of double stranded DNA triplets to generate this
highly sophisticated kind of gene mutant library.
The group of Dr. Roger Kornberg (Nobel Prize Laureate in Chemistry 2006) at
Stanford University will perform in vivo screens based on the library provided
by Sloning to identify relevant mutants of a S. cerevisiae RNA Polymerase II.
Jan Van den Brulle, Scientific Director at Sloning commented, “We are looking
forward to work together with Dr. Kornberg’s group. This project gives us again
the opportunity to demonstrate the power of our technology”.
Dr. Kornberg stated, "this mutant library will allow us to dissect and better
understand the transcription mechanism."
Link to the news release and to high-resolution pictures:
http://www.b3c.de/php/popup.php?id=101
About Sloning - www.sloning.com
Located in Munich, Germany, Sloning is a private company with the number one
technology for the synthesis of diverse genetic libraries. Diverse genetic
libraries are essential in the screening for new and improved therapeutic
proteins or proteins used in technical applications. Sloning uses Slonomics™ to
synthesize customised mutant libraries for its customers from the
biopharmaceutical, industrial biotech, agribiotech and food industries
worldwide. In particular, Sloning takes an ethical approach to synthetic biology
and is a founder member of the Industry Association of Synthetic Biology
formulating industry standards for biosafety and biosecurity.
Contact
Dr. Jan Van den Brulle, Scientific Director
+49 89 80 95 – 0
email: j.vandenbrulle@sloning.de
| |
|
